Corinne Hoesli secures major CFI funding to develop a robust organoid biomanufacturing platform for therapeutic innovation
April 21, 2026 – News from our researchers
Researcher Corinne Hoesli and her collaborators have been awarded more than $6 million in funding from the Canada Foundation for Innovation (CFI) for the BRAVO project – Robust and Advanced Biofabrication for Organoid Valorization.
This initiative aims to establish a complete organoid biomanufacturing pipeline, which are mini models of human tissues grown in the lab and used to more effectively assess the impact of new drugs. The platform will integrate quality control capabilities, tailored bioprocessing solutions, and transfer mechanisms to GMP-compliant environments, helping bridge the gap between research and clinical applications.
This project clearly demonstrates the leverage effect sought by Médicament Québec. By supporting the early stages of this interinstitutional collaboration between academia and industry, led by Corinne Hoesli, Médicament Québec’s funding has helped bring forward a structuring initiative that is now reaching a key milestone toward larger-scale deployment, with significant benefits for the Quebec and Canadian life sciences ecosystem.
Comments are closed.